Ofer Shpilberg

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Lorenz Trümper, Anders Österborg et al. · The Lancet Oncology · 2006 · 2.1K citations

Medicine, Oncology, Chemotherapy +11

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

Jesús F. San Miguel, Rudolf Schlag, Nuriet K. Khuageva et al. · New England Journal of Medicine · 2008 · 1.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

B Coiffier, E.A. Osmanov, Xin Hong et al. · The Lancet Oncology · 2011 · 1.6K citations

Medicine, Hematology, Pharmacotherapy +13

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Christian Gisselbrecht, Nicolas Mounier, Devinder Gill et al. · Journal of Clinical Oncology · 2010 · 1.6K citations · Full text

Medicine, Oncology, Chemotherapy +13

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Robert H. Collins, Ofer Shpilberg, William R. Drobyski et al. · Journal of Clinical Oncology · 1997 · 1.3K citations

Medicine, Hematology, Immunology +8